RESUMO
Induced pluripotent stem (iPS) cells are human somatic cells that have been reprogrammed to a pluripotent state. There are several hurdles to be overcome before iPS cells can be considered as a potential patient-specific cell therapy, and it will be crucial to characterize the developmental potential of human iPS cell lines. As a research tool, iPS-cell technology provides opportunities to study normal development and to understand reprogramming. iPS cells can have an immediate impact as models for human diseases, including cancer
Assuntos
Pesquisa Biomédica , Terapia Baseada em Transplante de Células e Tecidos , Células-Tronco Pluripotentes/citologia , HumanosRESUMO
The International Society for Stem Cell Research (ISSCR) task force that developed new Guidelines for the Clinical Translation of Stem Cells discusses core principles that should guide the responsible transition of basic stem cell research into appropriate clinical applications.
Assuntos
Tecnologia Biomédica/normas , Terapia Baseada em Transplante de Células e Tecidos/normas , Ensaios Clínicos como Assunto/normas , Guias de Prática Clínica como Assunto/normas , Transplante de Células-Tronco/normas , Animais , Tecnologia Biomédica/ética , Terapia Baseada em Transplante de Células e Tecidos/ética , Comitês de Monitoramento de Dados de Ensaios Clínicos/normas , Ensaios Clínicos como Assunto/ética , Humanos , Consentimento Livre e Esclarecido/normas , Monitorização Fisiológica/normas , Revisão por Pares/normas , Transplante de Células-Tronco/éticaRESUMO
The Juvenile Diabetes Research Foundation International (JDRF) was founded in 1970 by parents of children with juvenile diabetes to find a cure for diabetes and its complications through the support of research. The foundation was an early supporter of stem cell research, recognizing the promise of stem cells to quicken the pace of discovery for a cure for juvenile diabetes. The JDRF has committed considerable resources to supporting stem cell research in both the United States and abroad. In the United States, the organization has been an advocate on the state and national level for increased funding and for expansion of current federal policy restricting embryonic stem (ES) cell research.